阳光诺和：ABA001 注射液临床试验申请获得受理

Core Viewpoint - Sunshine Nuohe (688621.SH) has received the acceptance notice from the National Medical Products Administration for the clinical trial application of its research project ABA001 injection, which aims to treat hypertension [1] Group 1: Product Overview - ABA001 injection is a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) messenger RNA (mRNA), utilizing an N-Acetylgalactosamine (GalNAc) delivery system to precisely deliver the drug to liver cells [2] - The drug works by silencing AGT mRNA through the siRNA interference mechanism, thereby blocking the synthesis of AGT protein and fundamentally inhibiting the role of the Renin-Angiotensin-Aldosterone System (RAAS) in raising blood pressure [2] - Non-clinical studies indicate that a dosage of 1 mg/kg can significantly lower blood pressure, with good animal tolerance and high safety, potentially allowing for long-acting effects with administration every 3 to 6 months [2]